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Preface 
Endocrine disruptors (EDs) and combination effects of chemicals have 
been on the agenda in the EU and the Nordic countries for years. In 
2010 two Nordic workshops, one on criteria for EDs and one on com-
bination effects with focus on EDs, took place in Denmark. The discus-
sions on possible Member State initiatives to provide input to the EU 
processes were continued at a Nordic workshop in Helsinki in 2011. 
Key elements for the regulation of EDs are in process in Europe and 
important discussions are ongoing especially with regard to the estab-
lishment of criteria for the identification of endocrine disrupting sub-
stances, whether there is a threshold for endocrine disrupting effects 
and how EDs should be managed within relevant EU regulatory sys-
tems. With regards to combination effects, a roadmap for the further 
EU work has been presented and it is now time for more detailed dis-
cussions regarding various scientific issues and the most efficient way 
for regulatory intervention. 
A continued contribution to the ongoing discussions and processes in 
relation to both subjects is highly prioritized in the Nordic countries. 
The aim of the workshop held in Oslo in November 2013 was to pro-
vide a status of the EU and international processes in relation to regula-
tion of EDs and combination effects, to highlight the current main regu-
latory challenges, to exchange views and discuss possible ways forward 
and to increase the level of knowledge and competence within the rele-
vant authorities in the Nordic countries. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
1. Summary and conclusions 
The workshop “Road to regulation of endocrine disruptors and combina-
tion effects” was organised and chaired by the Danish Environmental 
Protection Agency and supported by the Nordic Council of Ministers. The 
workshop was held in Oslo on the 20th and 21st of November 2013 and 
hosted by the Norwegian Environment Agency (Appendix A). There 
were 38 participants, mainly representatives from the national authori-
ties in Finland, Iceland, Sweden, Norway and Denmark (Appendix B). 
The main topics of the workshop were: 
 
 Current regulatory activities regarding endocrine disruptors (EDs) 
in the EU, OECD and globally – and main challenges for the 
authorities right now. 
 Identification of EDs and amendments of standard information 
requirements. 
 How to facilitate use of non-guideline studies for identification of 
EDs. 
 Combination effects. 
 
Invited speakers presented their views and observations on these four 
main topics. After the presentations, all participating countries were 
invited to give short updates on their thoughts, views and activities 
within the area followed by plenary discussions on the topics. 
The workshop served as a good arena for the Nordic countries to up-
date each other on ongoing work and national prioritisations. At the end 
of the workshop it was decided to revitalise the Nordic network for EDs 
and to establish a Nordic network for combination effects. Furthermore, 
input in relation to the ED identification criteria impact assessment was 
considered important and the possibilities for a Nordic contribution 
were discussed. 
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It was in general agreed that increased cooperation and networking 
between the Nordic countries can be valuable to stay updated with the 
ongoing activities within the fields of EDs and combination effects. Each 
country has limited resources and usually only a few experts working 
within these fields, and therefore the possibilities for networking and 
sharing the workload can be valuable. 
 
2. Session 1 – Setting the  
scene for the discussions  
on endocrine disruptors 
2.1 Keynote speech: Status of current regulatory  
activities regarding endocrine disruptors in the 
EU, OECD and globally – and the main challenges 
for the authorities right now 
Pia Juul Nielsen, Danish Environmental Protection Agency 
 
 
In her presentation, Pia Juul Nielsen gave an overview of ongoing ED re-
lated regulatory activities with a focus on the main challenges for the au-
thorities and thoughts on possible ways forward. There are many ongoing 
activities with regard to EDs in the EU, OECD and globally, and she high-
lighted the importance of focusing on consistency and coordination of 
these activities. Many years of dedicated research and test methods devel-
opment have paved the way for regulation of EDs. The Commission was 
expected to present an “ED package” in June 2013 comprising criteria for 
ED identification, a status for the implementation of the 1999 Community 
strategy on EDs and a proposal for a new revised strategy.  
Due to legal requirements in the biocidal and plant protection 
products regulations (BPR and PPPR) the Commission was expected by 
13 December 2013 to propose horizontal and hazard-based criteria for 
the identification of substances with endocrine disrupting properties. 
However, the Commission ED criteria proposal has been postponed 
after intervention of several stakeholders and will now await an im-
pact assessment with regard to plant protection products and biocides.  
It is a challenge to ensure the development of appropriate and horizon-
tal ED criteria to be used across a number of EU chemical legislations 
(REACH, PPPR, BPR) and to handle the interim criteria under BPR and 
PPPR in the period until the final criteria are established and agreed upon. 
However, EDs may be identified on a case-by-case basis as substances of 
very high concern (SVHCs) under REACH. The SVHC identification and 
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substance evaluation processes under REACH are arenas where one may 
obtain experience that may set standards for future ED identification.  
The ED criteria impact assessment is expected on a public consulta-
tion in the first part of 2014, as is the revised EU strategy on endocrine 
disruptors. In addition, the Commission is reviewing the authorisation of 
EDs under REACH. Important questions are whether EDs only should be 
granted authorisation via the socioeconomic route, i.e. whether the 
scope of Art. 60(3) should be expanded and whether a threshold for ED 
effects always can be established. In that regard, the existence of thres-
holds for EDs and the related uncertainties in determining such thres-
holds have been intensively debated. The decision on EDs in relation to 
thresholds may require a new approach for ED risk assessment (RA) to 
be considered.  
The focus on EDs in EU is further reflected by the 7th Environment 
Action Programme (7th EAP) in which one important goal is to minimize 
exposure to EDs and the coming years will include activities for reaching 
this goal. 
On a global level, the recent WHO/UNEP report “State of the Science 
of Endocrine Disrupting Chemicals – 2012” stated that there are still 
important uncertainties and knowledge gaps in our understanding of 
endocrine disrupting chemicals, however, there is enough knowledge 
for regulatory intervention with the aim to reduce exposures. Fur-
thermore, EDs was accepted as an emerging issue under SAICM in 
2012; the global strategic approach to international chemicals man-
agement.  
In relation to OECD activities several ED relevant test methods have 
been internationally accepted, but current test guidelines only cover 
estrogenic, androgenic, thyroid and steroidogenic (EATS) modalities. A 
detailed review paper on novel endpoints has recently been published 
(OECD 2012), but the importance of updating existing test methods 
with sensitive ED relevant endpoints and the inclusion also of end-
points that will detect effects occurring later in life was underlined. 
2.2 Thoughts, views and activities in the different 
countries 
All Nordic countries are following the process of development of ED 
regulation closely and work related to ED regulation is in general highly 
prioritized. EDs are included in the National chemicals action plans for 
all the Nordic countries, but the level and focus of the national activities 
 Road to regulation of endocrine disruptors and combination effects 13 
varies. Most countries highlighted the importance of gaining experience 
with SVHC identification (article 57 (f)) and substance evaluation under 
REACH in relation to identification of EDs.  
2.3 Discussion and conclusions 
Main discussion points for the ED work were related to the immediate 
possibilities of giving input to ongoing ED-related processes and the 
more long-term initiatives. 
While waiting for the criteria for identification for EDs, the im-
portance of actively using the processes already ongoing to identify and 
test ED substances was strongly stressed by several participants. In par-
ticular, the REACH SVHC identification process and the substance evalu-
ation processes give the opportunity for gaining experience in relation to 
evaluation of ED substances. The value of informal Nordic cooperation 
and networking within these areas was stressed. 
The issue of the possibility to require further testing for identification 
of EDs and its dependence on existing alerts for endocrine activity was 
debated. How to assure that appropriate screening tests and evaluations 
are performed to provide ED alerts and thus prioritize further testing? 
Use of the Danish (Q)SAR (Quantitative structure–activity relationship)  
database as well as adverse outcome pathways (AOPs) for EDs for this 
purpose was discussed.  
The importance of a continuous focus on the process of establishing 
ED identification criteria was underlined, in order to ensure the devel-
opment of appropriate and horizontal criteria. While waiting for the  
final criteria, the importance of ensuring that interim criteria for ED 
identification for plant protection products and biocides are practised in 
an appropriate manner was stressed.  
In relation to the threshold debate it was mentioned that scientists 
are divided in their view on this issue. Elements of these discussions 
include the question of whether some mode of actions (MoAs) are with-
out threshold whereas others are thresholded and whether it is possible 
or not to define a potential threshold with sufficient reliability, consider-
ing critical exposure periods for hormonal influence and lack of sensitiv-
ity of existing test guidelines. The implications of the conclusion that 
threshold cannot be set with sufficient certainty for EDs in general was 
discussed. Possible regulatory consequences of assuming a non-
threshold approach were also discussed. It may then be needed to de-
velop a new approach for RA of EDs as well as focusing on substitution. 
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It was also discussed whether a unified approach for threshold and non-
threshold substances could be developed. 
It was discussed whether it adds to increased protection of health and 
environment to pursue the identification of potential EDs and to include 
all identified EDs in the REACH candidate list regardless of whether the 
exposure is already adequately controlled and/or they are already identi-
fied as SVHCs for e.g. reproductive toxicity or carcinogenicity. The huge 
workload and expenses was weighted against a possible increased protec-
tion level. It was stated that in some cases there may be good reasons to 
proceed with ED identification and authorization/restriction processes 
since CMR (carcinogenic, mutagenic or toxic for reproduction) substance 
identification does not cover environmental effects, since ED identification 
is the first step toward grouping or read-across for these effects, and since 
regulation of EDs within some other EU legislations (e.g. cosmetics and 
toys) has not been decided yet. Furthermore, some of the other legisla-
tions lack the legal possibility to require further testing of substances.  
The possibilities for distinguishing EDs with high from EDs with low-
er concern were discussed. It was mentioned that it is not possible to 
conclude that disruption of one particular hormone system is more or 
less detrimental than effects on other hormonal axes. In addition, the 
aspects of sensitive windows of exposure and knowledge gaps makes 
ranking based on potencies very difficult and cannot be justified from a 
scientific point of view.  
In general it was agreed that increased cooperation and networking 
between the Nordic countries can be valuable and it was decided to revi-
talise the Nordic network for EDs. 
 
3. Session 2 – Identification of 
endocrine disruptors and 
amendments of standard  
information requirements  
3.1 Keynote speech: Proposal of how to update the 
standard information requirements in REACH, 
pesticides and biocides – a brief introduction to a 
testing strategy for identification of endocrine 
disruptors 
Sofie Christiansen, Division of Toxicology and Risk Assessment, National 
Food Institute, Technical University of Denmark and Henrik Holbech,  
Department of Biology, University of Southern Denmark 
 
 
This talk presented the report: DK Information/testing strategy for iden-
tification of substances with ED properties (Hass et al., 2013). The aim of 
the presented report is to contribute to development of inform-
ation/testing strategies for adequate identification of EDs in relation to 
both human health and the environment. 
The current standard information requirements (SIRs) are not suffi-
cient to adequately detect substances with ED properties for human 
health and the environment. By taking into account the limitations of 
current testing methods and available standard information for sub-
stances (high tonnage levels) it seems warranted to request more com-
prehensive investigations of ED properties for these substances. It is 
therefore proposed to enhance standard test methods and include new 
methods and endpoints in the existing SIRs.  
It is proposed that for all substances (Q)SAR models and in vitro as-
says for examining different ED modalities e.g. ER, AR, and steroido-
genesis interference should be conducted to elucidate whether there 
are alert(s) for further testing for ED effects.  
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The most important proposals for changes of the current SIRs are re-
placement and/or enhancements of the current guidelines to include 
endpoints sensitive to ED effects. This includes extension of tests to in-
clude ED related endpoints, making optional ED related endpoints man-
datory and perform read across.  
In addition a “test package” is proposed for already registered sub-
stances in REACH to detect substances with ED properties if the registra-
tion file/REACH related processes/screening show alerts for ED. The 
two different testing strategies are based on the data source from which 
a concern for ED effects is identified (1 – ED MoA through in vitro or 
(Q)SAR studies, and 2 – in vivo alerts from animal studies). This strategy 
could be used by industry to provide more comprehensive information 
with regard to the ED properties of substances. The authorities could 
also apply this strategy to require additional information or testing from 
industry. It was recommended to require information to elucidate 
whether higher tonnage substances under REACH (extensive human 
and/or environmental exposure) have ED properties.  
3.2 Thoughts, views and activities in the different 
countries  
The subject is of high interest in all Nordic countries which have over-
lapping but slightly different approaches to how to improve identifica-
tion of EDs. The activities in the different countries span from mechanis-
tic studies, method development, involvement in the OECD test guideline 
program, and substance evaluations, to recommendations for changes of 
the SIRs in current relevant regulations.  
3.3 Discussion and conclusions 
In the keynote presentation, it was concluded that ED effects are not well 
covered by the current SIRs, and that the most important and urgent areas 
for improvements are replacement and/or enhancement of methods and 
test guidelines in the SIRs to include endpoints for ED effects. There was in 
general agreement about the need for enhancement and/or replacement 
of the existing methods and test guidelines in the SIRs, although it was 
noted that a long time to implementation of new and/or enhanced meth-
ods and tests guidelines in relevant legislation is anticipated. 
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It was dicussed whether it would be possible to include in vitro data 
and (Q)SARs for SIRs in relevant regulations. This could help to identify 
substances with potential endocrine disrupting effects without or before 
changing the methods/test guidelines in the SIRs. Possibilities for using 
the Danish (Q)SAR database to aid in the prioritisation of chemicals for 
further testing was discussed. The Danish (Q)SAR database includes data 
points related to endocrine disruption (estrogen, androgen and thyroid 
receptor interactions) and will be publicly available by the end of 2014 
or early 2015. 
Challenges for obtaining funding of research on EDs and especially 
for test method development was discussed. The possibility for includ-
ing ED research in Horizon 2020 was highlighted.   
Several ideas for further work and collaboration within the field were 
discussed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
4. Session 3 – How to facilitate 
use of non-guideline  
studies for identification of 
endocrine disruptors 
4.1 Keynote speech: Development of methods for the 
evaluation of data for risk assessment and weight 
of evidence 
Anna Beronius, Department of Applied Environmental Science, Stockholm 
University  
 
 
In her talk, Anna Beronius presented a proposal for a new framework for 
the evaluation of in vivo toxicological studies for health RA of chemicals 
(Beronius et al., 2014) and discussed the development of an accompany-
ing weight-of-evidence approach. While studies conducted according to 
internationally validated and accepted test guidelines are generally con-
sidered to be reliable by default, non-guidelines studies, i.e. studies not 
conducted according to any standardized guidelines, are often ques-
tioned as to their reliability. This hampers the use of a lot of available 
toxicological data that could fill important information gaps in RA. The 
proposed framework aims at providing a transparent and structured 
two-tired approach for the qualitative evaluation of the reliability and 
relevance of toxicological studies. While the Klimisch score is currently 
widely used to assess reliability of toxicological data, it does not provide 
any clearly defined criteria for data evaluation and is of limited value for 
the assessment of non-guideline studies. Furthermore, existing methods 
for data evaluation do not provide any systematic criteria for assess-
ment of study relevance.  
Studies that do not fulfil the 11 Tier I reliability criteria in the proposed 
framework are generally not taken forward to the Tier II reliability and 
relevance evaluation. However, such studies may be included on a case-
by-case basis if judged to be of very high relevance or in the absence of 
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other data. The Tier II evaluation consists of 32 criteria for further evalua-
tion of study reliability as well as 8 items to be considered when assessing 
study relevance. The output to the Tier II assessment is an overall evalua-
tion of the study’s adequacy for health RA. A web-based tool using colour-
coding has been developed to aid the Tier II evaluation and is publically 
available free of charge online at www.scirap.org. SciRap (Science in Risk 
Assessment and Policy) is a web-based reporting and evaluation tool de-
veloped by researchers at the Stockholm University and the Karolinska 
Institute in Sweden, to facilitate and increase the use of non-guideline 
toxicity studies in RA.  
Study reporting requirements for regulatory RA purposes are very 
high and insufficient reporting is a current obstacle for the use of non-
guideline studies in RAs. Thus, in addition to the study evaluation tool, a 
checklist for the proper reporting of animal studies has been developed 
and is also available online (www.scirap.org). This webpage also con-
tains information and criteria related to evaluation of ecotoxicity studies 
for the purposes of environmental RA. 
Weight-of-evidence is a term that is often used in RA contexts but 
rarely defined. In general it refers to an approach where all relevant 
toxicity data is summarized, synthesized and interpreted to draw con-
clusions regarding the relationship between a chemical exposure and 
adverse health effect. This approach requires that all relevant data is 
considered, including non-guideline studies. Stockholm University has 
received funds to organize two international workshops to discuss and 
develop a weight-of-evidence evaluation approach for EDs. Such an 
approach needs to provide predefined study evaluation criteria, as well 
as a method and criteria for summarizing the weight from several 
studies and different lines of evidence, e.g. in vitro, in vivo and epide-
miological data, and a scheme for the classification of the results. The 
first workshop will be held in London in June 2014. 
4.2 Thoughts, views and activities in the different 
countries 
There was a general appreciation of the need for better procedures to 
increase transparency and ensure the inclusions and acceptance of non-
guideline studies in RA as well as initiatives to ensure a more complete 
reporting of animal studies.  
The importance of expert judgement for evaluation of chemical sub-
stances was pointed out. It was mentioned that a potential undesired 
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effect of detailed evaluation criteria may be that non-guideline studies 
become more similar to guideline studies with the potential down-side 
of reducing their more explorative nature.  
To ensure a better design and reporting of animal studies it was sug-
gested that journal editors should inform on the existence of reporting 
guidelines in their instructions to authors and that more of the study 
data are made available (individual data, raw data) to facilitate inde-
pendent evaluation of results. To counteract the problem of publication 
bias, the generation of a database of negative results was suggested. 
4.3 Discussion and conclusions 
For many substances suspected to be EDs, much information originates 
from studies that do not follow internationally agreed OECD test guide-
lines (non-guideline studies). A need is recognised to enable better use 
of non-guideline, peer-reviewed studies in the RA of EDs and to enhance 
the transparency of the entire weight-of-evidence evaluation.  
The framework proposed by Anna Beronius was discussed in more 
general terms. In response to the concern that strict evaluation criteria 
may have the undesired effects reducing the difference between guide-
line and non-guideline studies, it was pointed out that the proposed 
framework is flexible and allows for extensive use of expert judgement. 
All the reliability and relevance criteria do not need to be fulfilled, but 
they are meant to enhance a more systematic and transparent study 
evaluation.  
There was no detailed discussion on the actual parameters that 
should be included in the study evaluation. However, selected parame-
ters like substance ID, determination of sufficient sample size, assess-
ment of internal exposure, target tissue concentrations, dosing solution, 
positive control, stability of test compound, and blind scoring of data 
was touched upon. It appears that these parameters are considered in 
the proposed evaluation scheme. However, measurement of tissue con-
centrations is not included as it is not a requirement in the OECD guide-
lines, and in order not to include more criteria for non-guideline tests 
than for guideline tests.  
There was a great interest in how the framework performs and how 
resource demanding the process is. The evaluation tool is currently be-
ing tested and two workshops are planned to elaborate on the proposed 
weight-of-evidence framework. It was pointed out that the transparency 
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ensured by the framework aids the potential “secondary use” of the data 
(e.g. if a new evaluation is to be performed). 
The framework proposed by Anna Beronius is now going to be 
evaluated and journal editors, scientists and risk assessors will be in-
formed about the work. In the discussion it was mentioned that  
National Research Councils might contribute to increased use of such 
guidelines by requiring compliance with reporting guidelines for fund-
ing of animal studies. 
It was commented that there are two main reasons for why non-
guideline studies are often given less weight than guideline studies in 
RA; restricted funding of non-guideline studies making them less com-
prehensive than guideline studies and lack of knowledge of what is 
needed for regulatory purposes.  
The OpenTox project was mentioned in relation to the importance of 
efforts to facilitate dialogue concerning testing and evaluation processes 
(http://www.opentox.org/). 
The discussions reflected a general support for continued dialogue 
between researchers and regulators on how to increase the use of non-
guideline studies for regulatory purposes.  
 
5. Session 4 – Combination  
effects 
5.1 Keynote speech 1: Status of current regulatory 
frameworks and new activities regarding 
combination effects in the EU, OECD and globally 
– and the main challenges for the authorities 
right now  
Rikke Holmberg, Danish Environmental Protection Agency 
 
 
In her talk, Rikke Holmberg presented the development and current 
status on regulatory frameworks and activities regarding combination 
effects. Combination effects are today to a limited extent introduced in 
regulation of known chemicals and intentional mixtures. However, 
there are no instruments to address combination effects of chemicals 
across EU legislations.  
In 2009, a report on the state of the art of mixture toxicity (Kortenkamp 
et al., 2009) was published. The outcome of an expert workshop on combi-
nation effects the same year stated that cumulative RA of combination ef-
fects is necessary and feasible, but that there was a need to strengthen the 
regulatory basis (Kortenkamp and Hass, 2009). In 2012, the opinion on the 
toxicity and assessment of chemical mixtures (SCHER, 2012) was published 
and it was stated that dose addition should be used as default if MoA is simi-
lar or not known. High quality data for single substances is needed for as-
sessment of combination effects, but under REACH compliance checks have 
shown that less than 10% of registrations are without deficiencies making 
assessment of combination effects even more challenging. In addition, the 
threshold debate may also influence the assessment of combination effects, 
as it is assumed by dose addition that compounds below their individual no 
observed effect concentration (NOECs) can act additively and induce biolog-
ic effects.  
An interservice and interagency ad hoc group addressing the challenges 
posed by introducing combination effects in RA of chemicals is planned to 
be established by the Commission as a follow-up to the Commission Com-
24 Road to regulation of endocrine disruptors and combination effects 
munication on combination effects of chemicals in 2012. The milestones of 
the group are to develop technical guidelines to promote consistent as-
sessment of prioritized mixtures across the different pieces of EU legisla-
tions by June 2014, and to publish a final report on experiences and pro-
gress on assessment of chemical mixtures by June 2015.  
In the 7th EAP the 2020 goal is that combination effects of chemicals 
and safety concerns related to EDs are addressed across all relevant EU 
legislations. By 2015 the goal is to undertake horizontal measures to 
ensure appropriate regulatory approaches, and by 2018 to develop an 
EU strategy for a non-toxic environment. 
The POPs Review Committee under the Stockholm Convention has 
agreed on guidance on toxic interactions stating that toxic interac-
tions should be taken into account when feasible in the Committee’s 
future work with developing risk profiles for POPs (persistent organ-
ic pollutants). 
There is a need to establish knowledge on actual exposures and driv-
ers for toxicity, recognize scientific advances and react on current 
knowledge. Until knowledge gaps are filled it might be an option to focus 
on priority mixtures and establish a methodology on how to get from 
priority mixtures to real life exposures. However, how should these pri-
ority mixtures be selected, and would they address the human health 
and environmental concerns that we are constantly exposed to many 
different chemicals from many sources and pathways? 
Some straight forward solutions regarding combination effects were 
proposed. One approach is to consider combination effects between 
chemicals based on common adverse outcome instead of common MoA 
(EFSA, 2013a). Another approach would be to look at the possibility to 
include some extra mixture toxicity considerations when risk character-
isation ratios (RCRs) are between 0.1 and 1. An extra mixture assess-
ment factor (MAF) could also be introduced to account for possible 
combination effects. Yet another option would be to use read across and 
grouping of chemicals directly as seen in the registrations. The possible 
options also need to be defined in a legal point of view. 
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5.2 Keynote speech 2: Is it only a few substances that 
drive the toxicity of combination effects? How to 
prioritize between mixtures? And how to proceed 
with regards to a more pragmatic approach for 
regulation of combination effects? 
Henrik Sundberg, KEMI 
 
 
There are several challenges when it comes to assessment of combina-
tion effects. Today, the scope of combination effects is set by legislative 
borders, which could potentially pose a liability problem. In the future 
the scope should ideally be to consider all possible combination effects 
with the overall aim to prevent unacceptable effects. But what adverse 
effects are unacceptable and which organisms should we protect in our 
RA – i.e. what are the protection goals? 
The same chemical can come from different sources (i.e. aggregated ex-
posure) and compounds in the same mixture can be covered by different 
regulations. For example, compounds occurring together in waste water 
treatment plants might be regulated by REACH, the BPR and the water 
framework directive. In some cases the different compounds in a mixture 
are regulated under the same legislation while in other cases the different 
compounds in a mixture are regulated under several legislations.  
It is generally regarded that there are only a few compounds driving the 
potential toxicity of a mixture. For realistic situations, however, it is very 
seldom major contributors of the potential toxicity are identified. In some 
cases observed adverse effects are caused by complex mixtures of chemi-
cals. Andersen and co-workers (Andersen et al., 2012, Wohlfahrt-Veje et al., 
2011, 2012a and 2012b) demonstrated that exposure of mixtures of pesti-
cides used under regulatory approved situations results in reproductive 
disorders among greenhouse workers but the main drivers for these effects 
could not be established. In other cases adverse effects are caused by cur-
rently unidentified chemicals (Balk et al., 2009; Fitzsimons et al., 2001). In 
addition, there are few examples where major contributors of the toxic 
potential in complex mixtures are identified, and numerous investigations 
have demonstrated that other substances than those we generally analyze 
are major contributors (Brack, 2003). 
It is quite evident that there is a limited ability to foresee adverse ef-
fects, especially considering long-term effects caused by realistic com-
plex exposures. Exposure models used in RA for predicting concentra-
tions of PPPs in surface waters, for instance, are demonstrated being 
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unreliable for realistic situations (Bach and Hollis, 2012, Knäbel et al., 
2012 and 2014). The application of assessment factors is not sufficient 
for considering realistic combination effects (Martin et al., 2013).  
There are several tools for assessing combination effects (summa-
rized in EFSA, 2013b). At a Nordic workshop it was proposed to add an 
extra MAF (Tørsløv et al., 2011), but there is a need to define how large 
the unknown is and to what extent it should be applied. Research is 
needed to assess in which contexts MAF can be scientifically advocated, 
and if the degree of unknown can be quantified. Considering combina-
tion effects in the short term it is important to start using available tools. 
One of the challenges is to evaluate which tool is best utilized. A compar-
ison between the RA with the situation in the field is needed to investi-
gate whether the RA is on the safe side.  
On a long term perspective, a change in legislation and RA might be 
necessary in order to embrace all possible combination effects. Perhaps 
the legislations should be designed to strive for reduced risk compared 
with the current situations instead of demonstrating unacceptable ef-
fects considering the severe inability to foresee adverse effects? 
5.3 Thoughts, views and activities in the different 
countries  
All Nordic countries are waiting for action to be taken by the European 
Commission, but are meanwhile investigating combined effects in differ-
ent contexts. Grouping of chemicals is of high priority in all countries. 
Combination effects are already assessed for active substances within 
pesticide products (biocides and plant protection products), and the 
Stockholm Convention has developed a guidance for considering combi-
nation effects when listing chemicals as POPs.  
5.4 Discussion and conclusions 
One of the questions that were raised during the discussion was how we 
can use the current knowledge to regulate the risk from combined expo-
sure? The possibility of using monitoring databases was discussed. The 
possibility of generally lowering the chemical pressure without knowing 
everything was also discussed. Along these lines, the Nordic proposal of 
reducing the allowed RCR from 1 to 0.1 under REACH – or in general 
reducing the allowed limit values to 1/10 of the tolerable daily intake, 
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was discussed. It was in general agreed that this way forward is still 
valid.  
The need for guidelines for assessment of combination effects in a 
regulatory perspective was discussed, and it was underlined that a hori-
zontal approach for assessing aggregated and cumulative exposure is 
preferred since the exposure comes from several sources; consumer 
products, environment, food, etc. It was a general agreement among the 
workshop participants that it is important to work on both aggregated 
and cumulative exposure (exposure to combinations of chemicals) in 
parallel, and for cumulative exposure, it was debated whether common 
assessment groups should build on common adverse effect. It was dis-
cussed how narrow grouping of substances should be. The possibilities 
for including background exposure of compounds with similar MoA as 
the ED substances under evaluation (e.g. pesticides) in the RA were also 
discussed.  
In general it was agreed that further Nordic networking and coopera-
tion within this field can be valuable and should be explored.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
6. Abbreviations 
AOP Adverse outcome pathway 
BPR Biocidal products regulation 
CMR Carcinogenic, mutagenic or toxic for reproduction  
7th EAP 7th Environment Action Programme 
EATS Estrogenic, androgenic, thyroid and steroidogenic  
ED Endocrine disruptor 
MAF Mixture assessment factor 
MoA Mode of action 
NOEC No observed effect concentration  
OECD Organisation for economic co-operation and development 
POP Persistent organic pollutant 
PPPR Plant protection products regulation 
(Q)SAR Quantitative structure–activity relationship 
RA Risk assessment 
RCR Risk characterisation ratio 
REACH Registration, evaluation and authorization of chemicals 
SAICM Strategic approach to international chemicals management 
SCHER Scientific committee on health and environmental risk 
SIR Standard information requirement 
SVHC Substance of very high concern 
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8. Oppsummering og  
konklusjoner 
Et arbeidsseminar “Road to regulation of endocrine disruptors and com-
bination effects” ble organisert og ledet av Miljøstyrelsen i Danmark med 
støtte fra Nordisk Ministerråd. Seminaret ble avholdt i Miljødirektoratets 
lokaler i Oslo den 20.–21. november 2013, med deltagelse fra myndighet-
ene i Finland, Island, Sverige, Norge og Danmark. 
Følgende hovedtemaer ble behandlet: 
 
 Pågående regulatorisk aktivitet vedrørende hormonforstyrrende 
stoffer (HFS) i EU, OECD og globalt og hovedutfordringer for 
myndighetene akkurat nå. 
 Identifisering av HFS og forbedring av standard informasjonskrav. 
 Hvordan legge til rette for bruk av studier som ikke følger OECD-
retningslinjer for identifisering av HFS. 
 Kombinasjonseffekter. 
 
Inviterte foredragsholdere presenterte de respektive temaene og sine 
synspunkter på disse. Etter de innledende presentasjonene ble det gitt en 
kort oppdatering om tanker, synspunkter og aktiviteter fra representanter 
fra hvert av de nordiske landene etterfulgt av diskusjoner i plenum. 
Arbeidsseminaret utgjorde en fin arena for de Nordiske landene til å 
oppdatere hverandre om pågående arbeid og nasjonale prioriteringer, 
samt å diskutere mulige samarbeid. Ved avslutningen av seminaret ble 
det avgjort at det nordiske nettverket for HFS skulle revitaliseres og at 
man skulle etablere er nordisk nettverk for kombinasjonseffekter. Vide-
re ble mulighetene for innspill til konsekvensvurderingen av kriteriene 
for identifisering av HFS diskutert.  
Det var generell enighet om at økt samarbeid mellom eksperter i de 
nordiske landene vil være nyttig for å sikre god innsikt i pågående aktivite-
ter vedrørende HFS og kombinasjonseffekter. Ettersom de enkelte landene 
har begrensede ressurser og gjerne få eksperter på disse områdene kan 
nettverkssamarbeid og muligheter til arbeidsdeling være verdifullt. 
 
  
9. Appendix A  
– Workshop programme 
NORAP Workshop, 20th–21st of November 2013  
Road to regulation of Endocrine Disruptors and Combination Effects. 
Miljødirektoratet, Strømsveien 96, Oslo 
 
Wednesday 20th of November  
10.00–17.00  
 Welcome and outline of the workshop 
  
Session 1 Setting the scene for the discussions on endocrine disrup-
tors 
 “Status of current regulatory activities regarding endo-
crine disruptors in the EU, OECD and globally – and the 
main challenges for the authorities right now” (Pia Juul 
Nielsen, DK EPA) 
 5 min update from each Nordic country about experi-
ences from REACH/EU process as well as thoughts, 
strategy and activities regarding the regulatory chal-
lenges 
 Discussion 
  
Session 2 How to improve identification of endocrine disruptors? –
amending the existing standard information require-
ments  
 “Proposal of how to update the standard information 
requirements in REACH, pesticides and biocides – and a 
brief introduction to a testing strategy for identification 
of endocrine disruptors” (Sofie Christiansen and Henrik 
Holbech, Danish Centre on Endocrine Disruptors) 
 Brief status of thoughts/views/activities in each of the 
Nordic countries regarding this issue  
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 Discussion 
  
Session 3 How to facilitate a systematic use of relevant data from 
non-guideline studies in Weight-of-Evidence approaches 
for identification of endocrine disruptors? 
 “How to develop and improve methods for evaluating 
reliability and relevance of data for risk assessment, as 
well as for conducting weight of evidence evaluations” 
(Anna Beronius, Stockholm University) 
 Brief status of thoughts/views/activities in each of the 
Nordic countries regarding this issue  
 Discussion 
Thursday 21st of November 
09.00–14.00  
 Good morning and outline of the day 
  
Session 4 Combination effects 
 A)”Status of current regulatory frameworks and new 
activities regarding combination effects in the EU, 
OECD and globally – and the main challenges for the 
authorities right now” (Rikke Holmberg, DK EPA) 
 B) “Is it only a few substances that drive the toxicity of 
combination effects? How to prioritize between mix-
tures? And how to proceed with regards to a more 
pragmatic approach for regulation of combination ef-
fects?” (Henrik Sundberg, KEMI) 
 C) Brief status of thoughts/views/activities in each of 
the Nordic countries regarding the issues outlined in A) 
and B)  
 D) Discussion 
  
Sum-up of discussion points and conclusions from the workshop discus-
sions  
  
End of the workshop 
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